

REFERENCES: UROTHELIAL CANCER

1. American Cancer Society. *Cancer Facts & Figures 2015*. Atlanta: American Cancer Society: 2015
2. Roth B1, Wissmeyer MP, Zehnder P, Birkhäuser FD, Thalmann GN, Krause TM, Studer UE. A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. *Eur Urol*. 2010 Feb;57(2):205-11
3. Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? *Nat Rev Urol*. 2011 Dec 13;9(1):41-51
4. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA; Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell*. 2014 Aug 14;158(4):929-44.
5. van Rhijn BW1, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. *Eur Urol*. 2009 Sep;56(3):430-42.
6. James ND1, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. *N Engl J Med*. 2012 Apr 19;366(16):1477-88.
7. Grossman HB1, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med*. 2003 Aug 28;349(9):859-66.
8. Raj GV1, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, Frenkel E. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. *Cancer*. 2011 Jan 15;117(2):276-82.
9. Bellmunt J1, Fougerey R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, Choueiri TK. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. *Ann Oncol*. 2013 Jun;24(6):1466-72.
10. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. *J Urol*. 1985 Mar;133(3):403-7.
11. Stadler WM1, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
12. von der Maase H1, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol*. 2000 Sep;18(17):3068-77.
13. Daniel Peter Petrylak, Thomas Powles, Joaquim Bellmunt, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz Zambrano, Howard A. Burris, Joseph W. Kim, Siew-leng Melinda Teng, Jean-Marie Bruey, Priti Hegde, Oyewale O. Abidoye, Nicholas J. Vogelzang. A phase Ia study of MPDL3280A (anti-PDL1):

Updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol 33, 2015 (suppl; abstr 4501)

14. Elizabeth R. Plimack, Joaquim Bellmunt, Shilpa Gupta, Raanan Berger, Robert B. Montgomery, Karl Heath, Jonathan Juco, Kenneth Emancipator, Kumudu Pathiraja, Jared K. Lunceford, Rodolfo F. Perini, Peter H. O'Donnell. Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33, 2015 (suppl; abstr 4502)